Surface Oncology has secured $35 million in Series A funding. Atlas Venture, Fidelity Biosciences, Lilly Ventures and New Enterprise Associates led the round with participation from other investors that included Amgen Ventures and Novartis Institute for Biomedical Research. In addition to the funding, Dr. Elliott Sigal, former head of R&D at Bristol Myers Squibb, has been added to the company’s scientific advisory board. Based in Cambridge, Mass., Surface Oncology is a developer of next-generation cancer immunotherapies.
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Surface Oncology, a new company developing next-generation cancer immunotherapies, announced today that it has closed a $35 million Series A investment round led by Atlas Venture, which initially seeded the company in 2014, Fidelity Biosciences, Lilly Ventures, and New Enterprise Associates (NEA). Also joining the Series A were Amgen Ventures, Novartis Institute for Biomedical Research (NIBR), and Elliott Sigal, MD, former head of R&D at Bristol Myers Squibb (BMS), who will also join the company’s scientific advisory board (SAB).
The company is advancing a number of programs toward clinical development that are designed to build on the success of first-generation immune therapies, targeting newly understood mechanisms responsible for enabling tumor cells to evade detection by the immune system.
“Immunotherapy is one of the most significant breakthroughs for cancer treatment in the past several decades, and while current approaches are transformative for the field, they remain insufficient,” said David Grayzel, MD, Chairman and acting Chief Executive Officer at Surface Oncology, and partner at Atlas Venture. “By targeting novel areas of biology at the intersection of innate and adaptive immunity, we hope to expand the arsenal of immunotherapies, with the goal of treating a greater number of patients across a wider range of tumor types than are addressed by these agents today.”